Voriconazole treatment for less-common, emerging, or refractory fungal infections.
about
Novel perspectives on mucormycosis: pathophysiology, presentation, and management.Histoplasmosis: a clinical and laboratory updateFusarium infections in immunocompromised patientsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveIntegrated therapy for HIV and cryptococcosisScedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist*Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other ConditionsTreatment of cryptococcosis in the setting of HIV coinfection.Genotyping of Fusarium Isolates from Onychomycoses in Colombia: Detection of Two New Species Within the Fusarium solani Species Complex and In Vitro Antifungal Susceptibility Testing.Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerScedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy.Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).Fungal infections in transplant and oncology patients.In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.Effects of voriconazole on Cryptococcus neoformans.International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole.Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theEffects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphismPrimary central nervous system phaeohyphomycosis: a review of 101 cases.Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi.Topical voriconazole as a novel treatment for fungal keratitis.Posaconazole as salvage therapy for zygomycosis.Skin Microvascular Thrombosis in Fusarium Infection in Two Early Biopsied Cases.Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infectionAntifungal clinical trials and guidelines: what we know and do not knowSerum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapyCorrelation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical hepatotoxicity associated with antifungal agents.Study on the effect of neem (Azadirachta indica A. juss) leaf extract on the growth of Aspergillus parasiticus and production of aflatoxin by it at different incubation times.Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds.How much European prescribing physicians know about invasive fungal infections management?Emerging fungal infections in immunocompromised patients.Voriconazole in the management of nosocomial invasive fungal infections.Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.
P2860
Q24530554-A5D5B13E-0B45-4302-BC12-1E24D5D34803Q24675642-03842DE2-0F2F-44C3-97F1-E21AD9CD2731Q24685627-652C93B7-F9D1-41A7-A230-7AC73241E9FBQ27009221-25EE7651-731E-4D3B-A46F-E78ECC447AF4Q28077707-770C1035-5E43-4469-A3B5-F4903C0F0C9EQ28315344-CBBB3D32-DD61-4908-9228-94EE352E721FQ29399166-9A7E3FB1-42C4-4CB1-861F-F69C6367E7AAQ30366117-4EDDFF17-3608-48F2-B195-331DDE502626Q31052986-29DA59B2-F476-4095-86FB-A0B9434C762AQ33188045-87A8237B-FDC8-435F-91FD-54AE14FD8B8AQ33490772-353EF2B5-B915-4F90-9578-903EC0B723B3Q33650105-D814A811-4903-4EDB-A401-58118BFD7F5AQ33824506-B8A7F94D-C50C-4FF2-9E38-00611CABFDE2Q33859215-57AA8EA4-B0EF-49E9-893F-9B9D51407007Q33896940-25F42EDC-6654-45A8-A7D8-77B6C9C29132Q33938075-FD445DBA-6755-4A34-BF4E-D2E5BFE0362FQ34020746-24A1F60C-2092-4289-A1A2-0CF66E25C5BDQ34045383-BF67CB76-3A47-42AD-9801-45129B5176C3Q34142180-22C35CE7-4928-431D-BAEA-878264604D45Q34151084-1F8CF98B-4A30-4850-8F7F-BCF198A54FE0Q34166590-6AE5B946-E28E-472C-9A43-1926B8ACC2A1Q34212799-7369ED05-FA4B-472B-821E-9F1E73EB4438Q34213621-0B742F64-AAAE-413C-9B0B-D76F2EE59AF7Q34286912-D0BD4F81-CF90-4006-B6B0-ED85FFA51E89Q34288185-6211C8FB-D1F1-42FC-9BFD-2D0C361F68DCQ34301534-DBCD0467-D47B-41D4-8197-CFFBDC3305B1Q34301611-AD4C2F2B-D5E3-4D28-9541-3BB3AD97CCF6Q34336048-5599CAC9-074A-4AD3-8E36-445F3A8F047EQ34352014-13587112-23C0-43F5-BC77-186B9D76136AQ34400255-C15F68A5-B671-4BAA-B771-34DE53EC2943Q34413393-F888D7DD-78DF-4A26-A33E-EA5A7E74924BQ34431984-825D7DEB-735B-4D6A-97B9-BDB8580E9345Q34532546-798BBE84-1A3F-4C48-A255-8AD3BF1A4B3AQ34546811-D2A52A76-659C-4B22-9161-63BBAF93B11CQ34724824-F93F34F5-8B33-4C22-B946-93D703245E47Q35127872-D0ECF92C-DB43-4D17-B896-24488BC1A2D7Q35131938-BEB14F87-053E-496C-BB17-BE6163D5C991Q35161571-1F09A2C9-3D85-474B-812B-D2C8A573BE49Q35166823-A83082E5-7F66-42F1-AC4E-E399F7D28B8BQ35231368-2802C8DE-DBC6-4846-A7C8-B0A79DCFC155
P2860
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
@en
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
@nl
type
label
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
@en
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
@nl
prefLabel
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
@en
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
@nl
P2093
P2860
P356
P1476
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
@en
P2093
Ana Espinel-Ingroff
Bertrand DuPont
Elizabeth Johnson
Gudrun Just-Nübling
Haran T Schlamm
Juliàn de la Torre-Cisneros
Kieren A Marr
Richard N Greenberg
Thomas J Walsh
P2860
P304
P356
10.1086/374557
P407
P577
2003-04-22T00:00:00Z